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Abstract 
Background: Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency exhibits considerable allelic heterogeneity 
which manifests with variable biochemical and clinical penetrance. It has long been thought that G6PD deficiency 
confers partial protection against severe malaria, however prior genetic association studies have disagreed with 
regard to the strength and specificity of a protective effect, which might reflect differences in the host genetic back‑
ground, environmental influences, or in the specific clinical phenotypes considered.
Methods: A case‑control association study of severe malaria was conducted in The Gambia, a region in West Africa 
where there is considerable allelic heterogeneity underlying expression of G6PD deficiency trait, evaluating the three 
major nonsynonymous polymorphisms known to be associated with enzyme deficiency (A968G, T542A, and C202T) 
in a cohort of 3836 controls and 2379 severe malaria cases.
Results: Each deficiency allele exhibited a similar trend toward protection against severe malaria overall (15–26 % 
reduced risk); however, in stratifying severe malaria to two of its constituent clinical subphenotypes, severe malarial 
anaemia (SMA) and cerebral malaria (CM), the three deficiency alleles exhibited trends of opposing effect, with risk 
conferred to SMA and protection with respect to CM. To assess the overall effect of G6PD deficiency trait, deficiency 
alleles found across all three loci were pooled. G6PD deficiency trait was found to be significantly associated with pro‑
tection from severe malaria overall (OR 0.83 [0.75–0.92], P = 0.0006), but this was limited to CM (OR 0.73 [0.61–0.87], 
P = 0.0005), with a trend toward increased risk for SMA, especially in fully‑deficient individuals (OR 1.43 [0.99–2.08], 
P = 0.056). Sex‑stratified testing largely comported with these results, with evidence suggesting that protection by 
G6PD deficiency trait is conferred to both males and females, though susceptibility to SMA may be restricted to fully‑
deficient male hemizygotes.
Conclusions: In a part of Africa where multiple alleles contribute to expression of G6PD deficiency trait, these find‑
ings clarify and extend previous work done in populations where a single variant predominates, and taken together 
suggest a causal role for G6PD deficiency trait itself with respect to severe malaria, with opposing effects seen on two 
major clinical subphenotypes.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is an X-linked enzyme disorder with a global distribu-
tion, affecting hundreds of millions of people worldwide 
[1]. It is a genetically heterogeneous trait, with hundreds 
of deficiency alleles of variable penetrance described in 
the literature [2], several having risen to polymorphic fre-
quencies [3]. Prevalence of G6PD deficiency geographi-
cally correlates with the historical distribution of malaria 
[4], an infectious disease thought to have highly heritable 
differences in burden [5, 6], and a major contributor to 
childhood morbidity and mortality in endemic areas [7]. 
As such, G6PD deficiency has long been hypothesised to 
be a target of positive selection owing to partial protec-
tion afforded against malaria [8–11].
Genetic epidemiological evidence examining this 
hypothesis has been lacking in clarity, however, with past 
case-control association studies differing with respect to 
the strength and specificity of a protective effect [12–18], 
and even whether such an effect exists at all [19]. The 
difficulty in interpreting past studies lies not only in rec-
onciling the different clinical phenotypes considered in 
each, but also in recognising different assumptions made 
in defining G6PD deficiency trait itself. With regard to 
the former, clinical phenotypes considered range from 
measures of malaria poorly correlated with disease bur-
den, such as parasite rate or density [12, 20, 21], to more 
extreme phenotypes pathognomonic for severe, life-
threatening malaria, including profound anaemia, res-
piratory distress, and cerebral manifestations such as 
convulsions or coma [13–15, 22]. Furthermore, World 
Health Organization criteria for diagnosis of severe 
malaria are broad, and include a wide range of symp-
toms and clinical findings, which vary substantially not 
only in terms of pathophysiology, but also with respect 
to prognostic value [23]. Interpreting trait carriage is 
also nontrivial in that G6PD deficiency is both a genetic 
and a biochemical trait. As a sex-linked genetic trait, 
hemizygous males and homozygous females fully express 
the deficiency trait, while heterozygous females exhibit 
incomplete or partial expression due to random X inac-
tivation [24, 25]. As a biochemical trait, enzyme activity 
can be assayed quantitatively, but overlapping activity 
distributions for the different genotypic categories make 
qualitative assessment imperfect [16, 26, 27].
The most common G6PD deficiency allele in sub-Saha-
ran Africa is the C202T (A-) variant, and studies of this 
mutation have driven most association studies in this 
region. However, while the C202T allele is predominant 
in east Africa [28], in West Africa there are several other 
deficiency variants (A968G, T542A, C680A) and The 
Gambia appears to be a notable exception to the general 
rule that 202T is the most prevalent allele. Recent data 
published by the MalariaGEN consortium has found 
opposing effects of the 202T allele on risk for specific 
severe malaria clinical subphenotypes, finding risk con-
ferred with respect to severe malarial anaemia, and a 
trend toward protection with respect to cerebral malaria 
[29]. Given the allelic heterogeneity present in The Gam-
bia and the robust clinical data that has been collected 
here over many decades [30], it represents a unique loca-
tion to assess whether the effects of the 202T allele on 
modifying risk for specific severe malaria subphenotypes 
hold true for other functional alleles, and for G6PD defi-
ciency trait as a whole, in an area where multiple alleles 
of variable penetrance contribute to overall prevalence of 
the trait [15, 31]. Presented here is a case-control associa-
tion study of severe malaria and two of its major clinical 
presentations in The Gambia, examining all major func-
tional alleles contributing to expression of G6PD defi-
ciency trait in the region.
Methods
Ethics statement
Ethics approval was granted by The Gambia Govern-
ment/Medical Research Council Joint Ethics Committee 
and by the Oxford Tropical Research Ethics Committee, 
and written informed consent was obtained from a par-
ent or guardian prior to enrolment.
Study cohort
The case-control cohort studied is comprised of 3836 
controls and 2379 severe malaria cases, recruited at the 
Royal Victoria Hospital in Banjul. Malaria cases were 
confirmed by thin blood smear, and designated as ‘severe’ 
following WHO criteria, with two partially overlapping 
clinical syndromes identified in the majority of cases: 
severe malarial anaemia and cerebral malaria. Severe 
malarial anaemia (SMA) is defined here as packed cell 
volume ≤15  % or haemoglobin ≤5 g/dl, while cerebral 
malaria (CM) is defined as having a Blantyre coma score 
≤3 in the absence of other obvious causes, e.g. hypogly-
caemia or meningitis. A total of 556 (23 %) of these cases 
met the definition for SMA and 890 (37 %) met that for 
CM, with 129 (5  %) cases fitting both definitions (these 
were excluded in the analysis of each clinical subphe-
notype). Control samples were derived from cord blood 
obtained from local perinatal clinics. A demographic 
summary of the cohort is provided in Table 1.
Laboratory and statistical methods
Genotyping was performed on genomic DNA that was 
whole genome amplified via either primer extension 
pre-amplification or multiple displacement amplifica-
tion reaction. Single nucleotide polymorphisms (SNPs) 
were then assayed via multiplexed genotyping on the 
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Sequenom MASSarray platform. Automated genotype 
calls were manually curated via visual examination of 
cluster plots and mass spectra, with ambiguous geno-
types re-coded as missing.
Data curation was performed using custom Perl scripts 
and the PLINK software package [32]. Gender designation 
was curated using additional X chromosome SNP data 
previously generated for these samples, using an inbreed-
ing coefficient test that recodes gender based on observed 
heterozygosity. Any remaining heterozygous genotypes 
found in males were coded as missing, and individuals 
with ambiguous gender were excluded from the analysis. 
No significant frequency differences were found across 
genders and SNP genotype distribution in female controls 
did not significantly deviate from expected Hardy-Wein-
berg proportions (P > 0.05, exact test).
Association testing was conducted using custom 
scripts written in R [33]. A logistic regression framework 
was employed, using a generalised linear model assum-
ing a binomial error distribution. In the additive (trend) 
model, male genotypes were coded 0/2, with females 
coded as 0/1/2, as suggested by Clayton [34] and in 
keeping with biochemical penetrance data [16, 26]. In 
sex-stratified tests, male hemizygotes and female het-
erozygotes were coded 1, with individuals lacking defi-
ciency alleles coded as 0.
Composite G6PD deficiency trait genotype was defined 
as the sum of deficiency alleles present at all deficiency 
loci (968G + 542A + 202T) for an individual. Thus, a 
male was coded as 0 or 2, based on the absence or pres-
ence of a single deficiency allele across the three loci, 
while a female with a total of one deficiency allele pre-
sent was coded as 1, and two deficiency alleles as 2 
(including 13 ‘compound heterozygote’ individuals pos-
sessing a single deficiency allele at two different loci). It 
should be noted that this composite genotype was never 
greater than two because this scenario would require 
two deficiency alleles to co-occur on the same chromo-
some. Full expression of the G6PD deficiency trait, i.e. 
complete enzyme deficiency, was a binary genotype (0 
or 1) inferred according to the absence or presence of 
one (male hemizygotes) or two (female homozygotes 
and compound heterozygotes) deficiency alleles in 
total across the three loci. Thus, a 202T male hemizgy-
gote, 968G/202T female compound heterozygote, and a 
542AA female homozygote would all be scored as 1 for 
full G6PD deficiency trait expression.
Estimated odds ratios (OR) were adjusted by including 
the following covariates: HbS (sickle locus) genotype, self-
reported ethnicity, and sex (omitted in sex-stratified tests). 
All odds ratios are presented here as ‘OR [95 % CI]’.
Results
Association testing of G6PD deficiency alleles
The case-control study population included a total of 
2379 Gambian children with severe malaria and 3836 
cord blood control samples drawn from the same region. 
Genotypes were obtained at four nonsynonymous poly-
morphic loci within G6PD known to be associated with 
enzyme deficiency, including A968G, T542A, C680A, 
and C202T (Table 2), in order to comprehensively survey 
the genetic diversity underlying G6PD deficiency in West 
Africa. Three of these four SNPs were found to be poly-
morphic, with C680A being the lone monomorphic vari-
ant. The 968G variant was found to be the most common 
deficiency allele in the data set, present at a frequency of 
6.6 % in controls, with 202T and 542A found at frequen-
cies of 3.2 and 1.2 %, respectively. Each deficiency allele 
was first tested for association with severe malaria over-
all, using an additive (trend) genetic model consistent 
with G6PD biochemical penetrance data [16, 26], with 
heterozygote females treated as intermediate between 
non-deficient and deficient individuals, the latter being 
comprised of hemizygote males and homozygote females. 
These tests revealed a similar signal of protection for all 
three deficiency alleles (Table  3), suggestive of 15–26  % 
reduced risk, with strong evidence for the higher-fre-
quency variant 968G (OR 0.84 [0.74–0.96], P = 0.010 ), 
and milder evidence for 542A (OR 0.74 [0.53–1.03], 
P = 0.071) and 202T (OR 0.85 [0.70–1.03], P = 0.091).
Table 1 Demographic summary table
Summary of cases and controls stratified by ethnicity, divided by gender, severe malaria phenotype, and mean age (months)
Total (M, F) Control Case (SMA, CM) Age (SMA, CM)
FULA 1007 534, 473 670 337 82, 116 44.7 30.9, 50.9
JOLA 938 493, 445 476 462 100, 183 52.7 33.3, 58.2
MANDINKA 1981 1070, 911 1084 897 216, 341 51.1 35.7, 55.7
OTHER 1434 689, 745 1078 356 77, 140 53.6 38.6, 60.2
WOLLOF 855 456, 399 528 327 81, 110 47.0 29.0, 54.6
TOTAL 6215 3242, 2973 3836 2379 556, 890 49.8 33.5, 55.9
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Stratified testing of two major clinical subphenotypes
As severe malaria encompasses several clinical syn-
dromes that differ with respect to pathophysiology 
and prognostic value, stratified association testing was 
performed on each of the two major clinical subphe-
notypes predominant in The Gambia, severe malarial 
anaemia (SMA) and cerebral malaria (CM). Although 
these subphenotype tests were not equally powered to 
detect signals of association due to sample size differ-
ences (NSMA = 556, NCM = 890), they nonetheless sug-
gested a differential direction of disease association with 
respect to SMA and CM for all three G6PD deficiency 
alleles (Table 3). While deficiency alleles seemed to con-
fer protection against CM (968G: OR 0.73 [0.58–0.91]; 
542A: OR 0.47 [0.23–0.99]; 202T: OR 0.82 [0.60–1.11]), 
they exhibited a modest, but consistent trend toward sus-
ceptibility for SMA (968G: OR 1.09 [0.88–1.35]; 542A: 
OR 1.36 [0.87–2.11]; 202T: OR 1.09 [0.79–1.49]). Inter-
estingly, the 542A allele, which causes a more extreme 
enzyme deficiency state (WHO class 2,   1–2  % residual 
G6PD activity [35]), was associated with more extreme 
effect sizes for both subphenotypes– greater risk to SMA 
and greater protection from CM– than either 968G 
or 202T, which are of milder biochemical penetrance 
(WHO class 3,  10–20 % residual G6PD activity [36]).
Association of G6PD deficiency trait with severe malaria
Since a consistent direction of association was observed 
with respect to SMA and CM for all three deficiency 
variants, and given that each contributes to the overall 
prevalence of G6PD deficiency trait in The Gambia, it 
made sense to consider them as a unit and examine the 
central hypothesis concerning the association of G6PD 
deficiency trait itself with severe malaria. Specifically, it 
was asked whether possession of one or more deficiency 
alleles at any of the three loci was associated with sus-
ceptibility to severe malaria. Thus, G6PD deficiency trait 
status was inferred using a composite genotype which 
represented the sum of deficiency alleles across all three 
loci, with this genotype scored in the same way as all 
other genotypes were, namely that hemizygous-deficient 
males were treated as equivalent to homozygous-defi-
cient females, with heterozygous females being interme-
diate. Additionally, a binary composite genotype inferring 
presence or absence of full expression of the trait (i.e. full 
G6PD enzyme deficiency) was compiled, where presence 
of the trait required either one (male hemizygotes) or two 
(female homozygotes) deficiency alleles in total across 
the three loci. In these association tests (Table 3; Fig. 1), 
it was found that while G6PD deficiency trait exerted a 
strong protective effect against severe malaria overall 
(OR 0.83 [0.75–0.92], P = 0.0006), this protective effect 
was limited to CM (OR 0.73 [0.61–0.87], P = 0.0005 ), 
with a trend toward increased risk conferred to SMA, 
especially in fully-deficient individuals (OR 1.43 [0.99–
2.08], P = 0.056), consistent with effects seen for the 
202T deficiency allele alone in work recently published 
by the MalariaGEN consortium [29]. Importantly, this 
Table 2 Functional SNP summary table
For each functional SNP, the dbSNP identifier, common name, GRCh37 coordinate, major/minor alleles, amino acid residue change, and WHO biochemical 
classification are shown
SNP dbSNP ID Alias Position Alleles Amino acid change Class
A968G rs76723693 Betica‑Selma 153761240 A/G Leu323Pro 3
C680A rs137852328 Mexico City 153762340 C/A Arg227Leu 3
T542A rs5030872 Santamaria 153762655 T/A Asp181Val 2
C202T rs1050828 A‑ 153764217 C/T Val68Met 3
Table 3 Tests of association for G6PD deficiency SNPs
Frequency ALL SMA CM
Control Case (SMA, CM) OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
N = 3836 N = 2379 (556, 890)
HbS 0.072 0.013 (0.010, 0.007) 0.16 (0.12–0.21) 1.1e−38 0.16 (0.09–0.29) 2.9e−09 0.11 (0.06–0.19) 8.0e−15
A968G 0.066 0.054 (0.077, 0.048) 0.84 (0.74–0.96) 0.0102 1.09 (0.88–1.35) 0.4212 0.73 (0.58–0.91) 0.0060
T542A 0.012 0.007 (0.014, 0.005) 0.74 (0.53–1.03) 0.0706 1.36 (0.87–2.11) 0.1727 0.47 (0.23–0.99) 0.0483
C202T 0.032 0.023 (0.031, 0.021) 0.85 (0.70–1.03) 0.0906 1.09 (0.79–1.49) 0.6065 0.82 (0.60–1.11) 0.1970
G6PD_trait 0.113 0.085 (0.130, 0.078) 0.83 (0.75–0.92) 0.0006 1.14 (0.96–1.36) 0.1401 0.73 (0.61–0.87) 0.0005
G6PD_trait (full) 0.063 0.050 (0.084, 0.047) 0.80 (0.63–1.01) 0.0661 1.43 (0.99–2.08) 0.0557 0.68 (0.46–1.00) 0.0524
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differential direction of association contrasts with the 
consistent strong protective effect across both SMA and 
CM clinical subphenotypes observed for sickle cell trait 
(Table 3; Fig. 1).
Sex‑stratified association testing
As G6PD deficiency is an X-linked trait, and the subject 
of gender-specificity has been conflicting in previous 
association studies of severe malaria [12–15], sex-strat-
ified association tests were also conducted to examine 
how signals of association might vary between hemizy-
gous males and heterozygous females. It is important to 
note that these tests differ with respect to: (a) statistical 
power, as female heterozygotes are more common than 
male hemizygotes, and (b) interpretation with respect to 
biochemical penetrance, as hemizygous males are fully-
deficient, while female heterozygotes are only partially-
deficient. Such caveats notwithstanding, in these tests 
(Table  4), evidence of protection from severe malaria 
overall was found for both male hemizygotes (OR 0.75 
[0.58–0.96], P = 0.023) and female heterozygotes (OR 
0.74 (0.60–0.91) P = 0.0045), with this protective effect 
confined to CM for both males (OR 0.67 [0.45–1.02], 
P = 0.061) and females (OR 0.54 [0.38–0.77] P = 0.0006 ). 
The trend toward susceptibility observed for SMA was 
only observed in fully-deficient male hemizygotes (OR 
1.41 [0.96–2.08], P = 0.083), especially those carry-





































Fig. 1 G6PD trait association tests—estimated odds ratios. Results from association tests using a composite G6PD genotype to infer G6PD defi‑
ciency trait status, where composite genotype is the total number of variant alleles present across all three deficiency SNPs (A968G, T542A, and 
C202T) in an individual (‘G6PD trait’). Presence or absence of full expression of the trait (i.e. full G6PD enzyme deficiency) was also tested, where 
presence of the ‘full’ expression of the trait required presence of one (male hemizygotes) or two (female homozygotes) deficiency alleles in total 
across the three loci (‘G6PD trait [full]’). Also shown are association test results for HbS (red). Estimated OR with 95 % CI is shown for association with 
severe malaria overall (ALL), as well as for each subphenotype (SMA, CM)
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P = 0.051), although the lack of a similar trend in female 
heterozygotes is likely a reflection of their intermediate 
deficiency state. Interestingly, the most common G6PD 
deficiency allele across most of Africa, 202T, was found 
to be protective against severe malaria overall and the 
CM subphenotype only in female heterozygotes. Asso-
ciation testing of fully-deficient female homozygotes was 
limited due to low frequencies, and provided inconclu-
sive results.
Discussion
In examining multiple G6PD deficiency alleles in The 
Gambia, it was found that such alleles were associated 
with protection from severe malaria overall, but exhib-
ited differential effects with respect to two important 
clinical presentations of severe malaria, conferring pro-
tection from cerebral malaria (CM) and increasing risk 
for severe malarial anaemia (SMA). Taken together with 
prior work from populations where a single variant, 
C202T (A-), predominates, there is compelling evidence 
for a direct, causal role for G6PD deficiency trait in mod-
ification of clinical malaria subphenotypes, confirming 
past results demonstrating protection from CM [14, 22], 
as well as the more recently elucidated association with 
SMA [29]. Indeed, while the allelic heterogeneity pre-
sent in The Gambia presents a challenge with respect to 
achieving adequate statistical power to detect true effects 
among the multiple lower frequency variants present, in 
analysing these variants in tandem one not only reduces 
type I error, but also more directly assesses G6PD defi-
ciency trait itself independent of the genetic background 
upon which any particular variant lies.
As this study was limited to just one country, with 
its own distinct genetic background and environmen-
tal exposure history, including its own unique pattern 
of exposure to malaria, it will be important that further 
investigation be conducted in as many study populations 
in as diverse a range of geographic areas as possible, and 
there is ongoing work toward this end being conducted 
by the MalariaGEN consortium (manuscript in prepara-
tion). As there is substantial variation in the biochemi-
cal penetrance of G6PD deficiency alleles, it will also be 
useful for future work to include enzyme activity assays 
when feasible.
The present study provides the somewhat paradoxical 
result that a single gene can be associated with protec-
tion from and susceptibility to disease from the same 
infectious agent. This highlights the fact that severe 
malaria comprises distinct clinical presentations, and 
the extent to which these syndromes differ from one 
another. These findings are not unexpected, then, given 
that G6PD deficiency is known to predispose individuals 
to haemolytic anaemia in the presence of oxidant stresses 
from infection, drugs, and diet [37]. As the stronger sig-
nal of association is associated with cerebral malaria, the 
subphenotype more predictive of severe morbidity and 
mortality [30, 38], these findings are consistent with the 
malaria protection hypothesis, and suggest that further 
association studies at G6PD should distinguish between 
the different presentations of severe malaria.
The differential association patterns seen here also sug-
gest possible mechanistic differences between sickle cell 
trait (HbS) and G6PD deficiency in the modulation of 
malaria clinical phenotypes.
Table 4 Gender-stratified tests of association
Male (hemizygotes) Frequency ALL SMA CM
Control Case (SMA, CM) OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
N = 1941 N = 1301 (309, 478)
A968G 0.073 0.050 (0.084, 0.046) 0.70 (0.51–0.95) 0.0235 1.19 (0.72–1.95) 0.4961 0.62 (0.37–1.05) 0.0772
T542A 0.011 0.009 (0.026, 0.003) 0.84 (0.40–1.80) 0.6625 2.55 (1.00–6.52) 0.0505 0.28 (0.04–2.11) 0.2167
C202T 0.032 0.026 (0.042, 0.028) 0.87 (0.56–1.34) 0.5256 1.36 (0.68–2.72) 0.3834 0.94 (0.49–1.83) 0.8628
G6PD trait 0.118 0.087 (0.155, 0.079) 0.75 (0.58–0.96) 0.0231 1.41 (0.96–2.08) 0.0832 0.67 (0.45–1.02) 0.0608
Female (heterozygotes) Frequency ALL SMA CM
Control Case (SMA, CM) OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
N = 1895 N = 1078 (247, 412)
A968G 0.120 0.112 (0.148, 0.086) 0.87 (0.68–1.11) 0.2656 1.14 (0.74–1.76) 0.5654 0.63 (0.42–0.95) 0.0285
T542A 0.026 0.012 (0.022, 0.012) 0.43 (0.23–0.80) 0.0084 0.71 (0.25–2.03) 0.5244 0.41 (0.15–1.16) 0.0942
C202T 0.063 0.039 (0.048, 0.029) 0.67 (0.46–0.97) 0.0355 0.83 (0.41–1.69) 0.6065 0.49 (0.25–0.95) 0.0345
G6PD trait 0.202 0.160 (0.212, 0.124) 0.74 (0.60–0.91) 0.0045 0.99 (0.68–1.45) 0.9776 0.54 (0.38–0.77) 0.0006
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Sickle cell homozygous and heterozygous states have 
been variously reported to affect invasion and growth in 
vitro [39, 40], or to decrease parasite density in natural 
[41–43] and experimental [41, 44] settings. Modulation 
of acquired immunity [45], impaired rosetting [46] or 
reduced cytoadherence [47] may also reduce the survival 
of infected HbS erythrocytes and/or mitigate processes 
of inflammation, and thus might explain the protection 
seen against both forms of severe malaria in this study.
Studies of parasite phenotypes inside the G6PD-defi-
cient erythrocyte have been more equivocal. While some 
have found evidence of invasion preferences [48] or aber-
rant in vitro growth phenotypes [49], others have not 
[50, 51]. Similarly, evidence of decreased parasite density 
in vivo is mixed for both Plasmodium vivax [11, 21] and 
Plasmodium falciparum [12, 14, 20]. This raises the pos-
sibility that the protection afforded by G6PD deficiency 
against cerebral malaria might depend on genetic back-
ground or operate through some mechanism other than 
parasite survival inside the enzyme-deficient red cell. 
Given that G6PD is an important housekeeping enzyme 
with a wide distribution in the body, it is interesting to 
consider, for example, how its role in endothelial function 
(via nitric oxide synthase [52, 53]), or in the respiratory 
burst of immune cells (via NADPH oxidase [54]), might 
contribute to malaria protection.
Importantly, differences in the protection afforded by 
HbS and G6PD deficiency highlight the need to study 
clinical biomarkers and conduct in vitro experiments 
relevant to severe manifestations of malaria. Ultimately, 
if knowledge gained from investigations surrounding the 
malaria protection hypothesis is to inform clinical treat-
ment, a better understanding of the molecular mecha-
nisms as they relate to severe disease will be crucial.
Conclusions
In a region of West Africa with significant functional 
allelic heterogeneity, these data confirm that G6PD defi-
ciency state is protective against severe malaria, but in 
contrast to sickle cell trait, this protection is limited to 
the CM subphenotype, with possible increased risk con-
ferred to SMA. These results support the malaria protec-
tion hypothesis, but also suggest important mechanistic 
differences between the malaria-protective mechanisms 
of G6PD deficiency versus sickle cell trait.
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